Related Experiment Video

Updated: Mar 30, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K

Metabolic Mechanisms of Drug Resistance in Leukemia

Birgit Knoechel1, Jon C Aster2

  • 1Department of Pediatric Oncology, Dana Farber Cancer Institute and Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.

Cell Metabolism
|November 5, 2015
PubMed

Insights

Tumor cells reprogram metabolism to resist drugs. PI3K/AKT signaling drives a metabolic switch to aerobic glycolysis in T-cell acute lymphoblastic leukemia (T-ALL), impacting drug resistance.

Area of Science:

  • Oncology
  • Cancer Metabolism
  • Molecular Biology

Background:

  • Tumor cells exhibit metabolic reprogramming, a hallmark of cancer.
  • The link between metabolic alterations and drug resistance remains poorly understood.
  • Notch-dependent T-cell acute lymphoblastic leukemia (T-ALL) is a significant hematologic malignancy.

Purpose of the Study:

  • To investigate the relationship between metabolic reprogramming and drug resistance in cancer.
  • To elucidate the role of PI3K/AKT signaling in metabolic pathway selection.
  • To understand the metabolic dependencies in Notch-dependent T-ALL.

Main Methods:

  • Analysis of metabolic pathways in T-ALL cells.
  • Investigation of PI3K/AKT signaling activation.
  • Assessment of metabolic shifts in response to signaling pathway modulation.

Main Results:

  • PI3K/AKT signaling activation was identified as a key driver of metabolic reprogramming in T-ALL.
  • A metabolic switch from glutaminolysis to aerobic glycolysis was observed.
  • This metabolic shift is associated with the development of drug resistance in T-ALL.

Conclusions:

  • PI3K/AKT signaling orchestrates a metabolic shift towards aerobic glycolysis in T-ALL.
  • Targeting this metabolic reprogramming may offer novel therapeutic strategies for T-ALL drug resistance.
  • Understanding cancer cell metabolism is crucial for overcoming treatment failure.

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.5K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K